SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
In summary, once the diagnosis of SMM is done, the evaluation of the risk of progression to
MM is crucial in order to plan an appropriate management, always risk-adapted. The best option
continues being the inclusion of patients in clinical trials if available and if this is not the case,
early treatment can be initiated. There are some open questions like how to decide if a patient
is candidate to a preventive versus curative approach as well as how to correctly identify the
smoldering patient candidate to be early treated but clinical together with genomic markers will
help us to identify the best therapy for each patient with the objective of maintaining the
smoldering myeloma as a disease free of myeloma-defining events.
References:
1. Rajkumar SV, Landgren O, Mateos MV. Smoldering Multiple Myeloma. Blood 2015 May
14;125(20):3069-75
2. Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone in high-risk
Smoldering myeloma. N Engl J Med. 2013 Aug 1;369(5):438-47.
3. Lonial S, Jacobus S, Fonseca R, et al. Randomized Trial of Lenalidomide Versus Observation in
Smoldering Multiple Myeloma. J Clin Oncol. 2020 Apr 10;38(11):1126-1137.